ReviewCurrent treatment options in cardiovascular medicine2026
Emerging Light-Sheet Fluorescence Microscopy for Cardiac Vascular Imaging in Zebrafish.
Review in Current treatment options in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Purpose of Review: Cardiac vascular remodeling is central to cardiovascular development, injury, and regeneration, yet it remains difficult to resolve in three dimensions within the living, beating heart. This review critically evaluates emerging light-sheet fluorescence microscopy (LSFM) strategies for zebrafish cardiac vascular studies, distinguishes directly demonstrated cardiac applications from transferable methods established in other tissues, and defines quantitative endpoints needed for rigorous treatment-response assessment. Recent Findings: Cardiac-gated and four-dimensional LSFM, hybrid light-field/light-sheet imaging, multiscale acquisition, automated segmentation, and deep-learning-assisted reconstruction have enabled cardiac-cycle-resolved visualization of myocardial motion, intracardiac flow, endothelial migration, vascular remodeling, and regenerative responses. However, the evidence base is uneven: several approaches are validated directly in the zebrafish heart, whereas others remain enabling technologies whose cardiac microvascular utility is inferred from noncardiac applications. Summary: LSFM can serve as a powerful discovery platform when fluorescent reporters, motion synchronization, quantitative analysis, and biological validation are integrated prospectively. The field now requires standardized acquisition and reporting, explicit separation of measured and model-derived endpoints, validation of AI-assisted reconstructions, and coordinated confirmation in mammalian or human cardiovascular models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.